Main Content start here
Main Layout
Report Description

Report Description

Forecast Period

2027-2031

Market Size (2025)

USD 2.02 Billion

CAGR (2026-2031)

14.15%

Fastest Growing Segment

Cold Chain Management Systems

Largest Market

North America

Market Size (2031)

USD 4.47 Billion

Market Overview

The Global Cell & Gene Therapy Cold Chain Logistics Market will grow from USD 2.02 Billion in 2025 to USD 4.47 Billion by 2031 at a 14.15% CAGR. The Global Cell & Gene Therapy Cold Chain Logistics Market comprises specialized supply chain services dedicated to the temperature-controlled transport, storage, and handling of therapeutic biological materials. These logistics solutions are essential for preserving the efficacy of time-sensitive and temperature-critical cellular products, which often require cryogenic conditions throughout their transit. A primary driver supporting this market is the rapid expansion of the clinical development pipeline and the subsequent increase in regulatory approvals, which necessitates secure global distribution networks. According to the International Society for Cell & Gene Therapy, in 2024, the global sector pipeline grew to include 3,063 therapies, creating a substantial demand for specialized logistical handling to support these developing treatments.

Despite this growth, the market faces a significant challenge regarding the maintenance of stringent temperature stability across complex international supply chains. The requirement for ultra-low temperatures creates a high risk of product loss due to potential excursions, particularly during the last-mile delivery phase. Furthermore, infrastructure limitations in certain geographic regions can disrupt the continuity of the cold chain, complicating the distribution of these high-value therapeutics and potentially impeding the broader global expansion of the market.

Key Market Drivers

The Surge in Global Investments and Funding for Biopharmaceutical R&D drives market growth by financing expanded clinical programs and their associated logistics needs. Robust capital inflows enable developers to outsource premium, temperature-controlled supply chain services essential for preserving sensitive biological assets. According to BioSpace, October 2024, in the article 'Cell and Gene Therapy Investment Ticks Up After Hard Few Years', the sector attracted $10.9 billion in investment during the first half of 2024. This funding supports extensive research, creating substantial demand for specialized handling; according to Cryoport, Inc., in 2024, the company supported a record total of 691 global clinical trials as of September 30, reflecting the intense development activity fueled by this capital.

Accelerating Commercialization and Regulatory Approval of Cell and Gene Therapies shifts the focus from clinical shipments to high-volume commercial distribution. As therapies gain authorization, logistics networks must scale to ensure global patient access while adhering to strict standards. The transition to commercial stages demands rigorous cold chain infrastructure to prevent temperature excursions that could compromise high-value treatments. This expanding logistical burden is driven by successful market entries. According to World Courier, October 2024, in the 'CGT pipeline key insights for 2024 Q3', there are now 134 cell and gene therapies approved globally. This rising number of commercial products necessitates robust distribution networks capable of handling ultra-low temperature requirements.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the Global Cell & Gene Therapy Cold Chain Logistics Market is the difficulty of maintaining stringent temperature stability across increasingly complex international supply chains. As these high-value therapeutics often require ultra-low cryogenic temperatures, any thermal excursion or infrastructure failure during transit can result in irreversible product loss. This fragility is particularly detrimental when distributing to regions with inconsistent cold chain capabilities or prolonged last-mile delivery times, acting as a severe barrier to market accessibility and commercial scaling.

The impact of this logistical vulnerability is significantly amplified by the industry's global nature. According to the Alliance for Regenerative Medicine, in 2025, approximately 35 percent of global revenue from cell and gene therapy originated from markets outside the United States. This statistic indicates that a substantial proportion of the sector's economic value relies heavily on cross-border transport. Consequently, the risk of temperature deviations in diverse geographic landscapes creates financial uncertainty for developers, forcing them to limit market expansion plans and directly impeding the broader growth of the global logistics sector.

Key Market Trends

The Deployment of Cloud-Based Cell Orchestration Platforms is reshaping the sector by replacing manual tracking with integrated digital ecosystems. As autologous therapies scale, manufacturers require real-time vein-to-vein visibility to ensure Chain of Identity preservation across complex workflows. This digital shift minimizes human error and streamlines the scheduling of leukapheresis and infusion, effectively bridging the gap between manufacturing sites and clinical centers. According to TrakCel, November 2024, in the 'TrakCel Sets New Standards' announcement, the company's orchestration platform was selected to support five out of the seven autologous or matched allogeneic cell therapy products approved or expected to be approved in 2024.

Strategic Outsourcing to Specialized Niche Logistics Providers is becoming critical as biopharmaceutical companies seek to mitigate the risks of distributing high-value commercial products. Unlike standard pharmaceutical shipping, CGT logistics demand dedicated infrastructure, such as fleet management for cryogenic dewars and strict adherence to regulatory standards for regenerative medicine. Developers are increasingly partnering with vendors offering purpose-built capabilities rather than generalist freight forwarders to ensure product integrity. According to Cryoport, Inc., March 2025, in the 'Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results', revenue from supporting commercially approved cell and gene therapies rose to $26 million in 2024, a 20 percent increase year-over-year.

Segmental Insights

The Cold Chain Management Systems segment is currently the fastest-growing category in the Global Cell & Gene Therapy Cold Chain Logistics Market. This rapid expansion is driven by the imperative for real-time data visibility and strict adherence to regulatory standards enforced by institutions such as the FDA and EMA. As autologous and allogeneic therapies require precise temperature control, logistics providers are increasingly adopting integrated software to ensure Good Distribution Practice compliance. These systems are essential for maintaining the Chain of Identity and Custody, mitigating risk, and guaranteeing the integrity of sensitive biologic products throughout the supply chain.

Regional Insights

North America leads the global cell and gene therapy cold chain logistics market due to a high concentration of biopharmaceutical companies and extensive research activities. This position is supported by a strong regulatory framework established by the United States Food and Drug Administration (FDA), which facilitates the approval of complex therapeutic products. Furthermore, the region possesses an established healthcare infrastructure and specialized supply chain networks. These factors ensure the strict temperature control necessary to maintain the integrity of sensitive biological treatments throughout transportation and storage processes.

Recent Developments

  • In September 2024, UPS Healthcare entered into an agreement to acquire Frigo-Trans and its sister company BPL, two leading healthcare logistics providers based in Germany. This acquisition was aimed at strengthening the company’s end-to-end cold chain capabilities across Europe, specifically for time-critical and temperature-sensitive pharmaceutical products. The acquired network offers extensive temperature-controlled warehousing options, ranging from cryopreservation environments to ambient storage, which are vital for the integrity of cell and gene therapies. The Executive Vice President of UPS Healthcare emphasized that this move would accelerate their ability to support the fast-paced innovations occurring in the pharmaceutical industry.
  • In September 2024, Cryoport announced a strategic collaboration with SK pharmteco to deliver fully integrated logistics and manufacturing services to the biotechnology and pharmaceutical sectors. This partnership combined Cryoport’s extensive supply chain solutions, including biomaterial collection and specialized shipping systems, with the contract development and manufacturing expertise of SK pharmteco. The collaboration focused on streamlining the support for cell and gene therapy products, ensuring their safety and quality from early clinical stages through to commercial delivery. The Chief Executive Officer of Cryoport highlighted that this alliance aligns with their strategic goal to diversify revenue streams while supporting the advancement of lifesaving medical treatments.
  • In April 2024, CSafe launched a new line of reusable cryogenic dewars, designated as the CGT Cryo Series, which are specifically engineered for the secure transport of cell and gene therapy products. These advanced shipping solutions are capable of maintaining ultra-low temperatures below -150°C, a critical requirement for preserving the efficacy of temperature-sensitive biologic materials during transit. The new series integrates built-in real-time data tracking technology, providing manufacturers with maximum visibility and security for their high-value shipments. The Chief Executive Officer of CSafe stated that this innovation was developed to meet the unique and evolving needs of the regenerative medicine market.
  • In February 2024, DHL Supply Chain announced a strategic investment of $200 million to expand its life sciences and healthcare logistics capabilities within the United States. This significant expansion included the construction of new state-of-the-art warehouse facilities and the implementation of advanced technologies, such as autonomous mobile robots and enhanced temperature-controlled systems. The initiative was designed to address the increasing demand for specialized logistics, particularly for the storage and transport of complex cell and gene therapies. The President of Life Sciences and Healthcare at DHL Supply Chain noted that these resilient supply chains are essential for ensuring the safe delivery of critical treatments to patients.

Key Market Players

  • Cencora, Inc.
  • United Parcel Service, Inc.
  • Catalent, Inc.
  • BioLife Solutions, Inc.
  • Cryoport System LLC.
  • Atelerix Ltd.
  • Life Science Group Ltd
  • Yourway Biopharma Services Company
  • Bertelsmann SE & Co. KGaA
  • NMDP BioTherapies

By Component

By Services Offered

By Mode of Transportation

By Holding Temperature Range

By End User

By Region

  • Cryogenic Shippers
  • Cryogenic Storage Freezers
  • Ultra Low Freezers
  • Cold Chain Management Systems
  • Shipment and Storage Medium
  • Cryogenic Packout Kits
  • Others
  • Transportation
  • Storage
  • Packaging
  • Air
  • Ground
  • Water
  • Cryogenic
  • Refrigerated
  • Ambient
  • Others
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

Report Scope:

In this report, the Global Cell & Gene Therapy Cold Chain Logistics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Cell & Gene Therapy Cold Chain Logistics Market, By Component:
  • Cryogenic Shippers
  • Cryogenic Storage Freezers
  • Ultra Low Freezers
  • Cold Chain Management Systems
  • Shipment and Storage Medium
  • Cryogenic Packout Kits
  • Others
  • Cell & Gene Therapy Cold Chain Logistics Market, By Services Offered:
  • Transportation
  • Storage
  • Packaging
  • Cell & Gene Therapy Cold Chain Logistics Market, By Mode of Transportation:
  • Air
  • Ground
  • Water
  • Cell & Gene Therapy Cold Chain Logistics Market, By Holding Temperature Range:
  • Cryogenic
  • Refrigerated
  • Ambient
  • Others
  • Cell & Gene Therapy Cold Chain Logistics Market, By End User:
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Others
  • Cell & Gene Therapy Cold Chain Logistics Market, By Region:
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Cold Chain Logistics Market.

Available Customizations:

Global Cell & Gene Therapy Cold Chain Logistics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Cell & Gene Therapy Cold Chain Logistics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Cell & Gene Therapy Cold Chain Logistics Market Outlook

5.1.  Market Size & Forecast

5.1.1.  By Value

5.2.  Market Share & Forecast

5.2.1.  By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others)

5.2.2.  By Services Offered (Transportation, Storage, Packaging)

5.2.3.  By Mode of Transportation (Air, Ground, Water)

5.2.4.  By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others)

5.2.5.  By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others)

5.2.6.  By Region

5.2.7.  By Company (2025)

5.3.  Market Map

6.    North America Cell & Gene Therapy Cold Chain Logistics Market Outlook

6.1.  Market Size & Forecast

6.1.1.  By Value

6.2.  Market Share & Forecast

6.2.1.  By Component

6.2.2.  By Services Offered

6.2.3.  By Mode of Transportation

6.2.4.  By Holding Temperature Range

6.2.5.  By End User

6.2.6.  By Country

6.3.    North America: Country Analysis

6.3.1.    United States Cell & Gene Therapy Cold Chain Logistics Market Outlook

6.3.1.1.  Market Size & Forecast

6.3.1.1.1.  By Value

6.3.1.2.  Market Share & Forecast

6.3.1.2.1.  By Component

6.3.1.2.2.  By Services Offered

6.3.1.2.3.  By Mode of Transportation

6.3.1.2.4.  By Holding Temperature Range

6.3.1.2.5.  By End User

6.3.2.    Canada Cell & Gene Therapy Cold Chain Logistics Market Outlook

6.3.2.1.  Market Size & Forecast

6.3.2.1.1.  By Value

6.3.2.2.  Market Share & Forecast

6.3.2.2.1.  By Component

6.3.2.2.2.  By Services Offered

6.3.2.2.3.  By Mode of Transportation

6.3.2.2.4.  By Holding Temperature Range

6.3.2.2.5.  By End User

6.3.3.    Mexico Cell & Gene Therapy Cold Chain Logistics Market Outlook

6.3.3.1.  Market Size & Forecast

6.3.3.1.1.  By Value

6.3.3.2.  Market Share & Forecast

6.3.3.2.1.  By Component

6.3.3.2.2.  By Services Offered

6.3.3.2.3.  By Mode of Transportation

6.3.3.2.4.  By Holding Temperature Range

6.3.3.2.5.  By End User

7.    Europe Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.1.  Market Size & Forecast

7.1.1.  By Value

7.2.  Market Share & Forecast

7.2.1.  By Component

7.2.2.  By Services Offered

7.2.3.  By Mode of Transportation

7.2.4.  By Holding Temperature Range

7.2.5.  By End User

7.2.6.  By Country

7.3.    Europe: Country Analysis

7.3.1.    Germany Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.3.1.1.  Market Size & Forecast

7.3.1.1.1.  By Value

7.3.1.2.  Market Share & Forecast

7.3.1.2.1.  By Component

7.3.1.2.2.  By Services Offered

7.3.1.2.3.  By Mode of Transportation

7.3.1.2.4.  By Holding Temperature Range

7.3.1.2.5.  By End User

7.3.2.    France Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.3.2.1.  Market Size & Forecast

7.3.2.1.1.  By Value

7.3.2.2.  Market Share & Forecast

7.3.2.2.1.  By Component

7.3.2.2.2.  By Services Offered

7.3.2.2.3.  By Mode of Transportation

7.3.2.2.4.  By Holding Temperature Range

7.3.2.2.5.  By End User

7.3.3.    United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.3.3.1.  Market Size & Forecast

7.3.3.1.1.  By Value

7.3.3.2.  Market Share & Forecast

7.3.3.2.1.  By Component

7.3.3.2.2.  By Services Offered

7.3.3.2.3.  By Mode of Transportation

7.3.3.2.4.  By Holding Temperature Range

7.3.3.2.5.  By End User

7.3.4.    Italy Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.3.4.1.  Market Size & Forecast

7.3.4.1.1.  By Value

7.3.4.2.  Market Share & Forecast

7.3.4.2.1.  By Component

7.3.4.2.2.  By Services Offered

7.3.4.2.3.  By Mode of Transportation

7.3.4.2.4.  By Holding Temperature Range

7.3.4.2.5.  By End User

7.3.5.    Spain Cell & Gene Therapy Cold Chain Logistics Market Outlook

7.3.5.1.  Market Size & Forecast

7.3.5.1.1.  By Value

7.3.5.2.  Market Share & Forecast

7.3.5.2.1.  By Component

7.3.5.2.2.  By Services Offered

7.3.5.2.3.  By Mode of Transportation

7.3.5.2.4.  By Holding Temperature Range

7.3.5.2.5.  By End User

8.    Asia Pacific Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.1.  Market Size & Forecast

8.1.1.  By Value

8.2.  Market Share & Forecast

8.2.1.  By Component

8.2.2.  By Services Offered

8.2.3.  By Mode of Transportation

8.2.4.  By Holding Temperature Range

8.2.5.  By End User

8.2.6.  By Country

8.3.    Asia Pacific: Country Analysis

8.3.1.    China Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.3.1.1.  Market Size & Forecast

8.3.1.1.1.  By Value

8.3.1.2.  Market Share & Forecast

8.3.1.2.1.  By Component

8.3.1.2.2.  By Services Offered

8.3.1.2.3.  By Mode of Transportation

8.3.1.2.4.  By Holding Temperature Range

8.3.1.2.5.  By End User

8.3.2.    India Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.3.2.1.  Market Size & Forecast

8.3.2.1.1.  By Value

8.3.2.2.  Market Share & Forecast

8.3.2.2.1.  By Component

8.3.2.2.2.  By Services Offered

8.3.2.2.3.  By Mode of Transportation

8.3.2.2.4.  By Holding Temperature Range

8.3.2.2.5.  By End User

8.3.3.    Japan Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.3.3.1.  Market Size & Forecast

8.3.3.1.1.  By Value

8.3.3.2.  Market Share & Forecast

8.3.3.2.1.  By Component

8.3.3.2.2.  By Services Offered

8.3.3.2.3.  By Mode of Transportation

8.3.3.2.4.  By Holding Temperature Range

8.3.3.2.5.  By End User

8.3.4.    South Korea Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.3.4.1.  Market Size & Forecast

8.3.4.1.1.  By Value

8.3.4.2.  Market Share & Forecast

8.3.4.2.1.  By Component

8.3.4.2.2.  By Services Offered

8.3.4.2.3.  By Mode of Transportation

8.3.4.2.4.  By Holding Temperature Range

8.3.4.2.5.  By End User

8.3.5.    Australia Cell & Gene Therapy Cold Chain Logistics Market Outlook

8.3.5.1.  Market Size & Forecast

8.3.5.1.1.  By Value

8.3.5.2.  Market Share & Forecast

8.3.5.2.1.  By Component

8.3.5.2.2.  By Services Offered

8.3.5.2.3.  By Mode of Transportation

8.3.5.2.4.  By Holding Temperature Range

8.3.5.2.5.  By End User

9.    Middle East & Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook

9.1.  Market Size & Forecast

9.1.1.  By Value

9.2.  Market Share & Forecast

9.2.1.  By Component

9.2.2.  By Services Offered

9.2.3.  By Mode of Transportation

9.2.4.  By Holding Temperature Range

9.2.5.  By End User

9.2.6.  By Country

9.3.    Middle East & Africa: Country Analysis

9.3.1.    Saudi Arabia Cell & Gene Therapy Cold Chain Logistics Market Outlook

9.3.1.1.  Market Size & Forecast

9.3.1.1.1.  By Value

9.3.1.2.  Market Share & Forecast

9.3.1.2.1.  By Component

9.3.1.2.2.  By Services Offered

9.3.1.2.3.  By Mode of Transportation

9.3.1.2.4.  By Holding Temperature Range

9.3.1.2.5.  By End User

9.3.2.    UAE Cell & Gene Therapy Cold Chain Logistics Market Outlook

9.3.2.1.  Market Size & Forecast

9.3.2.1.1.  By Value

9.3.2.2.  Market Share & Forecast

9.3.2.2.1.  By Component

9.3.2.2.2.  By Services Offered

9.3.2.2.3.  By Mode of Transportation

9.3.2.2.4.  By Holding Temperature Range

9.3.2.2.5.  By End User

9.3.3.    South Africa Cell & Gene Therapy Cold Chain Logistics Market Outlook

9.3.3.1.  Market Size & Forecast

9.3.3.1.1.  By Value

9.3.3.2.  Market Share & Forecast

9.3.3.2.1.  By Component

9.3.3.2.2.  By Services Offered

9.3.3.2.3.  By Mode of Transportation

9.3.3.2.4.  By Holding Temperature Range

9.3.3.2.5.  By End User

10.    South America Cell & Gene Therapy Cold Chain Logistics Market Outlook

10.1.  Market Size & Forecast

10.1.1.  By Value

10.2.  Market Share & Forecast

10.2.1.  By Component

10.2.2.  By Services Offered

10.2.3.  By Mode of Transportation

10.2.4.  By Holding Temperature Range

10.2.5.  By End User

10.2.6.  By Country

10.3.    South America: Country Analysis

10.3.1.    Brazil Cell & Gene Therapy Cold Chain Logistics Market Outlook

10.3.1.1.  Market Size & Forecast

10.3.1.1.1.  By Value

10.3.1.2.  Market Share & Forecast

10.3.1.2.1.  By Component

10.3.1.2.2.  By Services Offered

10.3.1.2.3.  By Mode of Transportation

10.3.1.2.4.  By Holding Temperature Range

10.3.1.2.5.  By End User

10.3.2.    Colombia Cell & Gene Therapy Cold Chain Logistics Market Outlook

10.3.2.1.  Market Size & Forecast

10.3.2.1.1.  By Value

10.3.2.2.  Market Share & Forecast

10.3.2.2.1.  By Component

10.3.2.2.2.  By Services Offered

10.3.2.2.3.  By Mode of Transportation

10.3.2.2.4.  By Holding Temperature Range

10.3.2.2.5.  By End User

10.3.3.    Argentina Cell & Gene Therapy Cold Chain Logistics Market Outlook

10.3.3.1.  Market Size & Forecast

10.3.3.1.1.  By Value

10.3.3.2.  Market Share & Forecast

10.3.3.2.1.  By Component

10.3.3.2.2.  By Services Offered

10.3.3.2.3.  By Mode of Transportation

10.3.3.2.4.  By Holding Temperature Range

10.3.3.2.5.  By End User

11.    Market Dynamics

11.1.  Drivers

11.2.  Challenges

12.    Market Trends & Developments

12.1.  Merger & Acquisition (If Any)

12.2.  Product Launches (If Any)

12.3.  Recent Developments

13.    Global Cell & Gene Therapy Cold Chain Logistics Market: SWOT Analysis

14.    Porter's Five Forces Analysis

14.1.  Competition in the Industry

14.2.  Potential of New Entrants

14.3.  Power of Suppliers

14.4.  Power of Customers

14.5.  Threat of Substitute Products

15.    Competitive Landscape

15.1.  Cencora, Inc.

15.1.1.  Business Overview

15.1.2.  Products & Services

15.1.3.  Recent Developments

15.1.4.  Key Personnel

15.1.5.  SWOT Analysis

15.2.  United Parcel Service, Inc.

15.3.  Catalent, Inc.

15.4.  BioLife Solutions, Inc.

15.5.  Cryoport System LLC.

15.6.  Atelerix Ltd.

15.7.  Life Science Group Ltd

15.8.  Yourway Biopharma Services Company

15.9.  Bertelsmann SE & Co. KGaA

15.10.  NMDP BioTherapies

16.    Strategic Recommendations

17.    About Us & Disclaimer

Figures and Tables


Frequently asked questions

Frequently asked questions

The market size of the Global Cell & Gene Therapy Cold Chain Logistics Market was estimated to be USD 2.02 Billion in 2025.

North America is the dominating region in the Global Cell & Gene Therapy Cold Chain Logistics Market.

Cold Chain Management Systems segment is the fastest growing segment in the Global Cell & Gene Therapy Cold Chain Logistics Market.

The Global Cell & Gene Therapy Cold Chain Logistics Market is expected to grow at 14.15% between 2026 to 2031.

Related Reports

We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site or by closing this box, you consent to our use of cookies. More info.